Clinical Trials Logo
  1. Home
  2. Acute Liver Failure
  3. NCT00004467

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen

Acute Liver Failure Clinical Trial

Clinical Trial Summary

OBJECTIVES:

I. Determine the safety and efficacy of a short course (72 hours) of intravenous acetylcysteine in patients with acute liver failure for whom no antidote or specific treatment is available.

Clinical Trial Description

PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive intravenous acetylcysteine or placebo for 72 hours. Treatment must begin within 12 hours of hospitalization. Patients who advance to grade III or IV encephalopathy are eligible for liver transplantation.

Patients are followed at 3 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00004467
Study type Interventional
Source National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact
Status Completed
Phase Phase 3
Start date June 1998
Completion date November 2006
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05491135 - Hepatocyte Microbeads for Acute Liver Failure Phase 1/Phase 2
Terminated NCT01937130 - Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF Phase 2
Withdrawn NCT05940610 - The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure Phase 1/Phase 2
Terminated NCT01875874 - Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF) Phase 2
Not yet recruiting NCT01435421 - Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery N/A
Completed NCT00245310 - Indocyangreen Elimination in Cirrhosis and Acute Liver Failure N/A
Withdrawn NCT03629015 - Safety Study of Stemchymal® in Acute Liver Failure Phase 1
Recruiting NCT04621812 - Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Active, not recruiting NCT02833064 - Biomarkers in Liver Failure
Not yet recruiting NCT06285253 - miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial Phase 1
Recruiting NCT03882346 - Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients Phase 2
Recruiting NCT05689645 - F573 for Injection for the Treatment of Liver Injury/Failure Phase 2
Not yet recruiting NCT05772585 - Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy
Completed NCT00655304 - The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure N/A
Completed NCT00059267 - Prevention of Recurrent Hepatitis B After Liver Transplantation N/A
Active, not recruiting NCT05413083 - Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Withdrawn NCT04089969 - Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct N/A
Completed NCT02460510 - Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF N/A
Completed NCT01872767 - Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure N/A